JP2020514383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514383A5 JP2020514383A5 JP2019551984A JP2019551984A JP2020514383A5 JP 2020514383 A5 JP2020514383 A5 JP 2020514383A5 JP 2019551984 A JP2019551984 A JP 2019551984A JP 2019551984 A JP2019551984 A JP 2019551984A JP 2020514383 A5 JP2020514383 A5 JP 2020514383A5
- Authority
- JP
- Japan
- Prior art keywords
- drug composition
- compound
- weight
- protein
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 26
- 229940079593 drug Drugs 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- -1 carboxylate anion Chemical class 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 238000002296 dynamic light scattering Methods 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000962 organic group Chemical group 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 125000000743 hydrocarbylene group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475185P | 2017-03-22 | 2017-03-22 | |
| US62/475,185 | 2017-03-22 | ||
| PCT/US2018/023578 WO2018175592A1 (en) | 2017-03-22 | 2018-03-21 | Modified oligonucleotides and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514383A JP2020514383A (ja) | 2020-05-21 |
| JP2020514383A5 true JP2020514383A5 (cg-RX-API-DMAC10.html) | 2021-04-30 |
Family
ID=63586170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551984A Pending JP2020514383A (ja) | 2017-03-22 | 2018-03-21 | 修飾オリゴヌクレオチドおよびその治療上の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200046846A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3600439A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020514383A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20190123351A (cg-RX-API-DMAC10.html) |
| CN (1) | CN110636865A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018237139A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3057292A1 (cg-RX-API-DMAC10.html) |
| SG (1) | SG11201908771YA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018175592A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4213883A1 (en) * | 2020-09-16 | 2023-07-26 | Astrazeneca AB | Oligonucleotides conjugated to fatty acids |
| EP4398939A1 (en) * | 2021-09-10 | 2024-07-17 | Guardian Therapeutics, LLC | Fatty acid conjugates of nucleic acids |
| EP4755898A1 (en) * | 2023-08-02 | 2026-06-10 | Nitto Denko Corporation | Method for producing oligonucleotide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216844A1 (en) * | 1995-03-31 | 1996-10-03 | Drug Delivery System Institute, Ltd. | Amidite derivatives and oligonucleotide derivatives |
| US8969543B2 (en) * | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| US20090306178A1 (en) * | 2006-03-27 | 2009-12-10 | Balkrishen Bhat | Conjugated double strand compositions for use in gene modulation |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | ｓｉＲＮＡ 접합체 및 그 제조방법 |
| GB0910723D0 (en) * | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| WO2012165616A1 (ja) * | 2011-06-03 | 2012-12-06 | 国立大学法人北海道大学 | オリゴヌクレオチド誘導体、オリゴヌクレオチド誘導体を含む治療用医薬組成物及び診断用医薬組成物、並びにｍｉＲＮＡ機能抑制用オリゴヌクレオチド誘導体 |
| PL2796150T3 (pl) * | 2011-12-15 | 2021-08-30 | Bioneer Corporation | Nowe koniugaty oligonukleotydowe i ich zastosowanie |
| WO2015006740A2 (en) * | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| WO2015038938A1 (en) * | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| US10039809B2 (en) * | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US9803201B2 (en) * | 2015-03-17 | 2017-10-31 | Arrowhead Pharmaceuticals, Inc. | Disulfide-containing alkyne linking agents |
| MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
| WO2017030973A1 (en) * | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| MY193776A (en) * | 2015-09-22 | 2022-10-27 | Univ California | Modified cytotoxins and their therapeutics use |
-
2018
- 2018-03-21 CA CA3057292A patent/CA3057292A1/en not_active Abandoned
- 2018-03-21 US US16/492,642 patent/US20200046846A1/en not_active Abandoned
- 2018-03-21 EP EP18770600.7A patent/EP3600439A4/en not_active Withdrawn
- 2018-03-21 SG SG11201908771Y patent/SG11201908771YA/en unknown
- 2018-03-21 JP JP2019551984A patent/JP2020514383A/ja active Pending
- 2018-03-21 WO PCT/US2018/023578 patent/WO2018175592A1/en not_active Ceased
- 2018-03-21 KR KR1020197030864A patent/KR20190123351A/ko not_active Ceased
- 2018-03-21 AU AU2018237139A patent/AU2018237139A1/en not_active Abandoned
- 2018-03-21 CN CN201880026265.5A patent/CN110636865A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7355758B2 (ja) | ケモカイン受容体調節剤及びその使用 | |
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| ES2247371T3 (es) | Agonistas del receptor a3 de adenosina. | |
| JP7212683B2 (ja) | 抗がん剤としての環状ジヌクレオチド | |
| JP2019511491A5 (cg-RX-API-DMAC10.html) | ||
| CN1424913A (zh) | 抗病毒前体药物 | |
| TW201902517A (zh) | Ｒａｆ降解結合物化合物 | |
| RU2016146819A (ru) | Композиции и способы модулирования экспрессии рецептора гормона роста | |
| JP2023541427A (ja) | 骨格筋送達プラットフォーム及び使用方法 | |
| CN101932310B (zh) | 制备基于官能两亲分子或者大分子的纳米颗粒的方法和其用途 | |
| TNSN07154A1 (en) | Purine derivatives for use as adenosin a-2a receptor agonists | |
| JP2012528867A5 (cg-RX-API-DMAC10.html) | ||
| JP2013518036A5 (cg-RX-API-DMAC10.html) | ||
| JP2015517565A5 (cg-RX-API-DMAC10.html) | ||
| US20040116376A1 (en) | Adenosine A3 receptor agonists | |
| EP1804838A2 (en) | Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs | |
| JP2025512963A (ja) | ケモカイン受容体モジュレータ及びその使用 | |
| JP6358661B2 (ja) | 界面活性剤様化合物 | |
| JP2015526499A5 (cg-RX-API-DMAC10.html) | ||
| JP2006520359A5 (cg-RX-API-DMAC10.html) | ||
| KR20190123351A (ko) | 개질된 올리고뉴클레오티드 및 이의 치료 용도 | |
| EP1663181A2 (en) | Protein binding compounds | |
| US20250122208A1 (en) | Chemokine receptor modulators and uses thereof |